Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 3/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731829 | 1.00 | MERTK (0.38) | MERTKYAP1PRMT5PDK4LMNA | |
| SCHEMBL26925201 | 0.92 | LMNA (0.36) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL30732082 | 0.92 | LMNA (0.36) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL26636757 | 0.89 | PDK4 (0.46) | PDK4HTR6GPR119 | |
| SCHEMBL31433805 | 0.88 | YAP1 (0.36) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL30732266 | 0.88 | PRMT5 (0.38) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL26925378 | 0.88 | PRMT5 (0.38) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL30706114 | 0.86 | YAP1 (0.39) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL26925084 | 0.86 | YAP1 (0.39) | MERTKYAP1PRMT5LMNATP53 | |
| SCHEMBL30732055 | 0.86 | LMNA (0.36) | MERTKYAP1PRMT5LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | MERTK 4856/4885YAP1 367/4885PRMT5 4198/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | MERTK 4856/4885YAP1 367/4885PRMT5 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.